1.80
+0.045(+2.56%)
Currency In USD
| Previous Close | 1.76 |
| Open | 1.74 |
| Day High | 1.82 |
| Day Low | 1.66 |
| 52-Week High | 7.89 |
| 52-Week Low | 0.87 |
| Volume | 167,481 |
| Average Volume | 252,487 |
| Market Cap | 88.16M |
| PE | -0.93 |
| EPS | -1.94 |
| Moving Average 50 Days | 1.35 |
| Moving Average 200 Days | 2.02 |
| Change | 0.05 |
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
GlobeNewswire Inc.
May 19, 2025 11:00 AM GMT
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect to dose first patients and report preliminary dat
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
GlobeNewswire Inc.
May 17, 2025 11:15 AM GMT
Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with curren
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference
GlobeNewswire Inc.
May 06, 2025 11:00 AM GMT
BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today anno